Interprovincial variation in access to publicly funded pharmaceuticals: A review based on the WHO Anatomical Therapeutic Chemical classification system

Canadian Pharmaceutical Journal

Volumn 137, Issue 7, 2004, Pages 29-34

  MacDonald, Kara ^b   Potvin, Ken ^a  

^a Canada's Research Based Pharmaceutical Companies   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANADA; DRUG FORMULARY; HEALTH CARE ACCESS; HEALTH INSURANCE; HUMAN; REIMBURSEMENT; REVIEW; WORLD HEALTH ORGANIZATION;

EID: 7044269564     PISSN: 08286914     EISSN: None     Source Type: Journal    
DOI: 10.1177/171516350413700703     Document Type: Review

References (12)

1. Canadian Institute for Health Information. Drug expenditure in Canada 1985-2002:12 and Series C data tables. Ottawa (ON): The Institute; 2003.
2. Canadian Coordinating Office for Health Technology Assessment. Common drug review. Available: www.ccohta.ca/entry_e.html (accessed August 6, 2003).
3. Gregoire JP, MacNeil P, Skilton K, et al. Inter-provincial variation in government drug formularies. Can J Public Health 2001;92:307-12.
4. Anis AH, Guh D, Wang X. A dog's breakfast: prescription drug coverage varies widely across Canada. Med Care 2001;39:315-26.
5. World Health Organization. About the ATC/DDD system. Geneva: The Organization; 2004. Available: www.whocc.no/atcddd/ (accessed August 9, 2003).
6. Health Canada. Drug product database (DPD). Active products search [online database]. Ottawa: Health Canada; [no date]. Available: search.hc-sc.gc.ca/cgi-bin/query?mss=dpd/english/active/simple (accessed June-August 2003).
7. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley & Sons; 1981.
8. Levy AR, Gagnon YM. Canadian formulary decisions: does pharmacoeconomics matter? Pharm News 2002;9(1):47-55.
9. PausJenssen A, Singer P, Detsky A. Ontario's formulary committee: how recommendations are made. PharmacoEconomics 2003;21:285-94.
10. West R, Borden EK, Collet JP, et al. Evaluation of provincial procedures for drug listings specifically focussed on approaches to cost-effectiveness. Ottawa: Health Canada; 2001. Health Transition Fund Project NA246.
11. Laupacis A. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? CMAJ 2002;166:44-7.
12. West R, Borden EK, Collet JP, et al. "Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement. Can J Public Health 2002;93(6):421-5.